blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
The President has committed to supporting a National HIV/AIDS Strategy (NHAS) that is “grounded in the best science.” Scientific research efforts have greatly expanded our understanding of HIV/AIDS and produced a large number of critical tools and interventions to help us diagnose, prevent, and treat HIV. The past year has been particularly productive with important…
Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…
Since early in the HIV/AIDS epidemic, the National Institute of Allergy and Infectious Diseases (NIAID) has involved community representatives and advocates in the research process. The nature and scope of the community’s involvement have grown over the years, but the rationale behind these efforts remains the same: the people who might benefit from the research…
Co-authored by Scott Proestel, M.D., Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH
On September 18, 2011, we mark the fourth observance of National HIV/AIDS and Aging Awareness Day. The remarkable success of antiretroviral therapies in prolonging the lives of HIV-infected individuals who have access to and can tolerate these drugs has…
This has been a big year for the HIV community. One key event was June 5 — which marked 30 years since the first reported cases of AIDS in the United States. As one of the many efforts to recognize this important milestone, the U.S. Department of Health and Human Services (HHS) developed a series…
This week, over 5,000 delegates from around the world are attending the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome, Italy. This biannual conference is the world’s largest open scientific conference on HIV/AIDS, and provides “a unique opportunity for the world’s leading scientists, clinicians, public health experts and…
As the National Institute of Allergy and Infectious Diseases (NIAID) moves forward to restructure its HIV/AIDS Clinical Trials Networks and include a new network focused on infectious diseases other than AIDS, the Clinical Trial Units (CTUs) will continue to play a critical role in establishing, developing, and implementing the networks’ scientific research agendas. Additionally, we…
Last month the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) announced a joint effort to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs), including HIV/AIDS. Among the products targeted in the action are Medavir, Herpaflor, Viruxo, C-Cure, and Never An…
